Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273 pediatric COVID-19 vaccine study in children 6 months to under 12 years
2021-000281-15Phase 2
- Sponsor
- Moderna Inc
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran and elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moderna Inc. Primary endpoint: Number of participants with solicited local and systemic adverse reactions.
02
Drugs
elasomeranelasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000281-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000281-15.